Compare ANF & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANF | LEGN |
|---|---|---|
| Founded | 1892 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 1996 | 2020 |
| Metric | ANF | LEGN |
|---|---|---|
| Price | $101.41 | $22.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $116.00 | $69.33 |
| AVG Volume (30 Days) | 2.0M | ★ 2.2M |
| Earning Date | 03-04-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.16 | N/A |
| EPS | ★ 10.47 | N/A |
| Revenue | ★ $5,181,407,000.00 | $909,045,000.00 |
| Revenue This Year | $7.63 | $68.52 |
| Revenue Next Year | $4.09 | $48.63 |
| P/E Ratio | $9.84 | ★ N/A |
| Revenue Growth | 7.57 | ★ 74.75 |
| 52 Week Low | $65.40 | $20.21 |
| 52 Week High | $147.91 | $45.30 |
| Indicator | ANF | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 46.68 |
| Support Level | $98.80 | $20.21 |
| Resistance Level | $108.49 | $24.12 |
| Average True Range (ATR) | 5.35 | 0.98 |
| MACD | -4.40 | 0.43 |
| Stochastic Oscillator | 8.60 | 69.56 |
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumers through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Majority stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.